One In A Million: Aegerion Looks To Raise The Price Of Myalept
This article was originally published in The Pink Sheet Daily
Company sees “opportunity for a one-time price increase” when it takes over the lipodystrophy drug’s launch from AstraZeneca. At a current cost of about $325,000 per year, metreleptin already is on the ultra-high spectrum on par with other rare disease drugs.
You may also be interested in...
Two decades after the “obesity gene” was the hottest story in biotech, a product from that research is finally going to reach the market. But it is for a disease that occurs in about .0001% of the US population.
Sponsor will institute a registry to monitor patients taking the LDL cholesterol-lowering drug for homozygous familial hypercholesterolemia for 10 years, as part of an approval that is a likely template for Genzyme’s Kynamro.
The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.